Posted by Michael Wonder on 10 Mar 2023
Pfizer’s Zavzpret (zavegepant) migraine nasal spray receives FDA approval
10 March 2023 - Zavzpret is the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine in adults.
Pfizer today announced the US FDA has approved Zavzpret (zavegepant), the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.
